论文信息 - Empirical characteristics of litigation involving tissue plasminogen activator and ischemic stroke. - 字舞流文

Empirical characteristics of litigation involving tissue plasminogen activator and ischemic stroke.

B. Liang | J. Zivin

[1] B. Demaerschalk. Thrombolytic therapy for acute ischemic stroke: the likelihood of being helped versus harmed. , 2007, Stroke.

[2] J. Glauser. Will EPsʼ Reluctance to Embrace Thrombolysis for Stroke Lead to Lawsuits?: Part 2 in a Series , 2006 .

[3] J. Glauser. Will EPsʼ Reluctance to Embrace Thrombolysis for Stroke Lead to Lawsuits , 2006 .

[4] Michael I Weintraub,et al. Thrombolysis (Tissue Plasminogen Activator) in Stroke: A Medicolegal Quagmire , 2006, Stroke.

[5] Derek E. Bambauer,et al. Reasons why few patients with acute stroke receive tissue plasminogen activator. , 2006, Archives of neurology.

[6] L. Lisabeth,et al. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. , 2005, Annals of emergency medicine.

[7] Joseph P Broderick,et al. Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke: A Population-Based Study , 2004, Stroke.

[8] B. Liang. Layperson and physician perceptions of the malpractice system: implications for patient safety. , 2003, Social science & medicine.

[9] J. Glauser. Stroke and the Emergency Physician: Is tPA Standard of Care? , 2007 .